company background image
1AQ logo

Evofem Biosciences DB:1AQ Stock Report

Last Price

€0.18

Market Cap

€7.4m

7D

0%

1Y

-96.4%

Updated

01 Jan, 2023

Data

Company Financials +

1AQ Stock Overview

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health.

1AQ fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Evofem Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evofem Biosciences
Historical stock prices
Current Share PriceUS$0.18
52 Week HighUS$7.01
52 Week LowUS$0.16
Beta-1.27
1 Month Change0%
3 Month Change0.55%
1 Year Change-96.40%
3 Year Change-99.76%
5 Year Changen/a
Change since IPO-99.87%

Recent News & Updates

Recent updates

Shareholder Returns

1AQDE PharmaceuticalsDE Market
7D0%2.1%1.6%
1Y-96.4%-26.3%6.4%

Return vs Industry: 1AQ underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: 1AQ underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 1AQ's price volatile compared to industry and market?
1AQ volatility
1AQ Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1AQ's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 1AQ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a119Saundra Pelletierhttps://www.evofem.com

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.

Evofem Biosciences, Inc. Fundamentals Summary

How do Evofem Biosciences's earnings and revenue compare to its market cap?
1AQ fundamental statistics
Market cap€7.36m
Earnings (TTM)-€264.02m
Revenue (TTM)€14.54m

0.5x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1AQ income statement (TTM)
RevenueUS$15.57m
Cost of RevenueUS$5.06m
Gross ProfitUS$10.51m
Other ExpensesUS$293.21m
Earnings-US$282.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.29
Gross Margin67.49%
Net Profit Margin-1,816.04%
Debt/Equity Ratio-55.3%

How did 1AQ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.